Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine
- 15 December 2017
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 39 (1), 38-46
- https://doi.org/10.1002/bdd.2110
Abstract
Trifluridine (FTD) exhibits anticancer activities after its oral administration despite its hydrophilic nature. It was previously reported that concentrative nucleoside transporter (CNT) 1 mediates the apical uptake of FTD in human small intestinal epithelial cells (HIECs). In the present study, FTD was also identified as a substrate for equilibrative nucleoside transporter (ENT) 1 and ENT2 in transporter gene-transfected cells. An immunocytochemical analysis revealed that ENT1 was expressed at the basolateral and apical membranes of HIECs. Cellular accumulation increased in the presence of S-(4-nitrobenzyl)-6-thioinosine (NBMPR), an ENT selective inhibitor. Cytotoxicity in HIEC monolayers at low FTD concentrations was increased by NBMPR, and this may have been due to inhibition of the ENT-mediated basolateral transport of FTD by NBMPR. These results suggest that ENTs reduce the intestinal cytotoxicity of FTD by facilitating its basolateral efflux. On the other hand, the intracellular accumulation and cytotoxicity of FTD in HIECs were decreased at higher concentrations of FTD by NBMPR, and this may have been due to the NBMPR inhibition of the apical uptake of FTD, which has been suggested to be mediated by CNTs and ENTs. In conclusion, ENTs were responsible for intestinal transepithelial permeation by mediating the basolateral efflux of FTD after its uptake by CNT1 from the apical side, resulting in decreases in its intracellular accumulation and intestinal toxicity in humans. Equilibrative nucleoside transporters may also partially contribute to the low-affinity uptake of FTD across the apical membrane along with high-affinity CNT1.Keywords
This publication has 21 references indexed in Scilit:
- The antibodies against 5-bromo-2′-deoxyuridine specifically recognize trifluridine incorporated into DNAScientific Reports, 2016
- Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometryCancer Chemotherapy and Pharmacology, 2016
- Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5‐fluorouracil: a meta‐analysis of published trialsBritish Journal of Clinical Pharmacology, 2014
- Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumoursBritish Journal of Cancer, 2012
- In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in HumansDrug Metabolism and Disposition, 2011
- Involvement of Multidrug Resistance-Associated Protein 1 in Intestinal Toxicity of MethotrexatePharmaceutical Research, 2009
- In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placentaAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Identification of Influx Transporter for the Quinolone Antibacterial Agent LevofloxacinMolecular Pharmaceutics, 2006
- Cloning of the Human Equilibrative, Nitrobenzylmercaptopurine Riboside (NBMPR)-insensitive Nucleoside Transporter ei by Functional Expression in a Transport-deficient Cell LinePublished by Elsevier BV ,1998
- Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugsNature Medicine, 1997